

• Name:	Mehrdad Rakaee, PhD
• Current Position & Affiliation:	Associate Professor of Computational Pathology, Institute for Cancer Research,
• Country:	Norway

• Educational Background:

In 2019, Dr. Rakaee received his PhD in Biomedicine from the University of Tromso, Norway. He subsequently completed postdoctoral training in machine learning and genomics at the Lung Center, Brigham and Women's Hospital, Harvard Medical School.

• Professional Experience:

Dr. Rakaee is Associate Professor and Principal Investigator at Departmet of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital. His research focuses on computational pathology and precision oncology, with a particular emphasis on developing artificial intelligence models to improve prediction of immunotherapy response in solid tumors. He leads interdisciplinary teams of researchers and has supervised multiple PhD candidates and postdoctoral fellows across institutions.

Dr. Rakaee holds visiting and honorary fellow appointments at Brigham and Women's Hospital/Harvard Medical School (2020-present) and Imperial College London (2024-present), and actively collaborates with international partners in translational cancer research. His work integrates machine/deep learning, histopathology, and multi-omics data to derive clinically relevant biomarkers, with recent models demonstrating potential for clinical application in lung cancer.

In addition to his research leadership, Dr. Rakaee contributes to national/Scandinavian clinical studies such as TNM-I, IMPRESS and NIPU, where his team supports biomarker clinical validation, molecular data analysis and integration. He was awarded the 2024 Young Researcher of the Year from Oncology Forum, Norway.

• **Professional Organizations:** ASCO, ESMO, CPCAI (Consortium for Patient Centered Artificial Intelligence), InPred (Infrastructure for Precision Diagnostics), NACG (Nordic Alliance for Clinical Genomics), NLCG (Norwegian Lung Cancer Group).



• Main Scientific Publications:

h-index: 25; 55 peer-reviewed publications

1. **Rakaee, M**. et al. Deep Learning Model for Predicting Immunotherapy Response in Advanced Non–Small Cell Lung Cancer. **JAMA Oncol** 11, 109–118 (2025).

2. **Rakaee, M**. et al. Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial. **Annals of Oncology** 109181 (2023) doi:10.1016/j.annonc.2023.04.005.

3. **Rakaee, M**. et al. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC. **JAMA Oncol** 9, 51–60 (2023).

